GoldenGolden
Advanced Search
AlloVir

AlloVir

AlloVir (formerly ViraCyte) is a company that develops cell therapies for patients suffering from life-threatening virus-associated diseases.

All edits

Edits on 4 Jun, 2021
Erin Scherfner"prospector:312:154110"
Erin Scherfner edited on 4 Jun, 2021
Edits made to:
Infobox (+3 properties)
Infobox
Country
United States
Edits on 11 May, 2021
Golden AI"Funding autocalculation"
Golden AI edited on 11 May, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding type
Edits on 28 Mar, 2021
Golden AI"Found on funding round"
Golden AI edited on 28 Mar, 2021
Edits made to:
Infobox (+6 properties)
Infobox
Investors
Edits on 13 Aug, 2020
Lax Mariappan
Lax Mariappan edited on 13 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Founded date
2013
Edits on 4 Aug, 2020
Marie Gabrielle Laguna- Bedia
Marie Gabrielle Laguna- Bedia edited on 4 Aug, 2020
Edits made to:
Infobox (+1 properties)
Edits on 3 Aug, 2020
Lax Mariappan
Lax Mariappan edited on 3 Aug, 2020
Edits made to:
Infobox (+6 properties)
Infobox
Founder
Edits on 1 Aug, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 1 Aug, 2020
Edits made to:
Infobox (+1/-1 properties)
Infobox
Total funding amount (USD)
39,000,000
Total funding amount (USD)
159,000,000
Golden AI
Golden AI edited on 1 Aug, 2020
Edits made to:
Infobox (+1 properties)
Golden AI"Funding autocalculation"
Golden AI edited on 1 Aug, 2020
Edits made to:
Infobox (+1/-1 properties)
Infobox
Total funding amount (USD)
9,000,000
Total funding amount (USD)
39,000,000
Golden AI
Golden AI edited on 1 Aug, 2020
Edits made to:
Infobox (+1 properties)
Golden AI"Funding autocalculation"
Golden AI edited on 1 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
9,000,000
Golden AI
Golden AI edited on 1 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 31 Jul, 2020
Aime Anne Nisay
Aime Anne Nisay edited on 31 Jul, 2020
Edits made to:
Infobox (+1 properties)
Edits on 24 Mar, 2020
Meredith Hanel
Meredith Hanel edited on 24 Mar, 2020
Edits made to:
Infobox (+6 properties)
Article (+20 characters)
Article

Using the approach used for Viralym-M, AlloVir and Baylor College of Medicine are working together to develop an off-the-shelf therapy capable of targeting the COVID-19 causing virus, SARS-CoV-2 and potentially be effective against other similar viruses such as SARS-CoV, MERS-CoV and endemic coronaviruses. SARS-CoV-2-specific T cells are planned as a monotherapy and coronaviruses are planned to be incorporated into a preclinical stage therapy, ALVR106, aimed at community-acquired respiratory viruses. Viralym-M expects the therapy would improve outcomes for immunocompromised patients exposed to SARS-CoV-2 and other viruses.

Infobox
Full address
Kirby Grove 2925 Richmond Ave, Suite 1200 Houston, TX 77098
Industry
Location
Meredith Hanel
Meredith Hanel edited on 24 Mar, 2020
Edits made to:
Article
Article

Development of their cell therapies involves exposing donor T cells to secreted proteins called cytokines combined with viral fragments so that the immune cells learn to recognize and eliminate certain pathogens. Their therapy Viralym-M (ALVR105) aims to be an allogeneic, off-the-shelf multi-virus specific T-cell therapy targeting six common viral pathogens: Viralym-M completed phase 2 clinical trials in 2014.

...

ALVR106 is an allogenic off-the-shelf multi-virus specific T-cell therapy in development that targets four common community-acquired respiratory viruses which are respiratory syncytial virus, influenza, parainfluenza virus and human meta-pneumovirus.

Meredith Hanel
Meredith Hanel edited on 24 Mar, 2020
Edits made to:
Article (+1126 characters)
Categories (+2 topics)
Article

Development of their cell therapies involves exposing donor T cells to secreted proteins called cytokines combined with viral fragments so that the immune cells learn to recognize and eliminate certain pathogens. Their therapy Viralym-M (ALVR105) aims to be an allogeneic, off-the-shelf multi-virus specific T-cell therapy targeting six common viral pathogens: Viralym-M completed phase 2 clinical trials in 2014.

ALVR106 is an allogenic off-the-shelf multi-virus specific T-cell therapy in development that targets four common community-acquired respiratory viruses which are respiratory syncytial virus, influenza, parainfluenza virus and human meta-pneumovirus.

Using the approach used for Viralym-M, AlloVir and Baylor are working together to develop an off-the-shelf therapy capable of targeting the COVID-19 causing virus, SARS-CoV-2 and potentially be effective against other similar viruses such as SARS-CoV, MERS-CoV and endemic coronaviruses. SARS-CoV-2-specific T cells are planned as a monotherapy and coronaviruses are planned to be incorporated into a preclinical stage therapy, ALVR106, aimed at community-acquired respiratory viruses. Viralym-M expects the therapy would improve outcomes for immunocompromised patients exposed to SARS-CoV-2 and other viruses.

Categories
Edits on 18 Jan, 2020
Golden AI
Golden AI edited on 18 Jan, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Investors
Edits on 26 Nov, 2019
Golden AI
Golden AI edited on 26 Nov, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Investors
Edits on 24 May, 2019
Carla Faraguna
Carla Faraguna edited on 24 May, 2019
Edits made to:
Infobox (+4/--1 properties)
Timeline (+1 events) (+36 characters)
Description (+141 characters)
Article (+498 characters)
Topic thumbnail

AlloVir

AlloVir (formerly ViraCyte) is a company that develops cell therapies for patients suffering from life-threatening virus-associated diseases.

Article

AlloVir is working on the clinical development of novel cell therapies designed to restore T-cell immunity against virus-associated diseases in immunocompromised patients, including stem cell and organ transplant recipients. AlloVir built a technology platform developed by researchers at Baylor College of Medicine's Center for Cell and Gene Therapy.

...

Their therapy Viralym-M (ALVR105) aims to be an allogeneic, off-the-shelf multi-virus specific T-cell therapy targeting six common viral pathogens:

Infobox
Timeline

May 22, 2019

AlloVir joined ElevateBio protfolio.
Carla Faraguna"Initial topic creation"
Carla Faraguna created this topic on 24 May, 2019
Edits made to:
Topic thumbnail

 AlloVir

AlloVir (formerly ViraCyte) is a company that develops cell therapies for patients suffering from life-threatening virus-associated diseases.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.